INVO Bioscience Announces First Shipments of INVOcell Into Bolivia
BEVERLY, Mass., Dec. 21, 2010 /PRNewswire/ -- INVO Bioscience, Inc. (OTC Bulletin Board: IVOB ), a medical device company focused on treatment options for patients diagnosed with infertility, today announced the initial shipments of the INVOcell device into Bolivia. The initial order of INVOcell devices was purchased by The National Center for Fertility and Sterility (CENALFES). Under the direction of clinic director Dr. Joaquin Lopez Arana and embryologist Dr. Patricia Frias, CENALFES is the largest infertility treatment center in Bolivia, having assisted more than 4,000 infertility patients over the past 20 years resulting in more than 1,500 births. Bolivia represents the fourth country in South America where fertility clinics have ordered INVOcell.
Bolivia has approximately 5 fertility centers licensed to perform assisted reproductive procedures. According to the Bolivian Health Ministry there are more than 1.8 million infertile couples in Bolivia, however less than 1,000 couples per year engage in assisted reproductive procedures, largely due to costs. Clinical results have demonstrated outstanding effectiveness of the INVOcell process without many of the inherent expenses associated with traditional in-vitro fertilization (IVF) procedures.
Kathleen Karloff, chief executive officer for INVO Bioscience, commented, "The company continues to execute on its stated goal of introducing the INVOcell device and process to many of the key opinion leaders throughout the world that will influence expanded acceptance and use of our products. CENALFES is one the largest providers of infertility treatments in Bolivia, which we expect to become a strong reference to the exceptional capabilities of INVOcell. We look forward to continue working with the many physicians at CENALFES and elsewhere in Bolivia to offer the many suffering infertile patients a cost